• A new subset of human and murine type II NKT-T FH cells against Gaucher lipids that regulate B-cell immunity.
Introduction
Natural killer T (NKT) cells are distinct innate lymphocytes that recognize lipid/glycolipid antigens in the context of the major histocompatibility complex (MHC)-like molecule CD1d. 1 NKT cells are currently classified into 2 major subsets: type I or invariant NKT (iNKT) cells that express a semi-invariant T-cell receptor (TCR) and recognize the prototypic antigen a-galactosylceramide (a-GalCer), and type II or diverse NKT cells that use diverse TCR a and b chains and do not recognize a-GalCer (reviewed in Godfrey et al 2 ). The widely studied type I NKT cells are more prevalent than type II NKT cells in mice as compared with humans, whereas type II NKT cells comprise the dominant subset of human CD1d-restricted T cells. 3 Recent studies have begun to implicate a distinct regulatory role for type II NKT cells (or the type I/type II NKT balance) in several settings including autoimmunity, inflammation, obesity, and protection against tumors and pathogens. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] Sulfatide was the first antigen recognized as a target for murine type II NKT cells, and sulfatide-reactive T cells are currently the best-studied subset of murine type II NKT cells. 4, 6 Studies with murine transgenic or sulfatide-reactive NKT cells have suggested that these cells have a diverse but oligoclonal TCR repertoire and distinct genomic profile and mode of TCR binding compared with type I NKT cells. [16] [17] [18] [19] The spectrum of putative murine type II NKT ligands has now widened, and some of these ligands can be recognized by both type I and type II NKT cells. [20] [21] [22] [23] [24] [25] [26] [27] Importantly, there are some species-specific differences in ligand recognition between human and murine NKT cells. 23, 28 Understanding the diversity and functional properties of human type II NKT cells against defined lipids is therefore of great interest in view of their potential immunoregulatory role in several disease states. 4, 5 Dysregulation of glucosphingolipids (GSLs) has been demonstrated in several metabolic disorders, including Gaucher disease (GD) and obesity. 29, 30 GD is an inborn error of metabolism due to deficiency of the lysosomal enzyme glucocerebrosidase (acid-b-glucosidase [GBA] ). 30, 31 GBA deficiency leads to progressive lysosomal storage of b-glucosylceramide (b-GlcCer; GL1) and its deacylated product, glucosylsphingosine (Lyso-GL1; LGL1), most conspicuously in the mononuclear phagocytes. 32, 33 Elevated levels of these lipids can also be detected in circulation, leading to modest elevation in GL1 and a marked increase in LGL1 levels. 34 Analysis of fatty acid acyl compositions of spleen from GD patients reveals that b-glucosylceramide 22:0 (bGL1-22) and GL1-24:0 are the most abundant b-GlcCer species. 35, 36 The accumulation of lipids in GD patients is associated with a chronic progressive inflammatory state with an increase in inflammatory cytokines, activation of macrophages, and high There is an Inside Blood Commentary on this article in this issue.
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incidence of B-cell activation, manifest as polyclonal and monoclonal gammopathy. 32, [37] [38] [39] [40] Interestingly, chronic inflammation has been observed in glucocerebrosidase-deficient mice with minimal substrate accumulation lacking classically engorged macrophages, 37 suggesting involvement of immune cells other than just macrophages in stimulating inflammation and B-cell activation. Here, we have analyzed the host response to GD lipids to gain insights into mechanisms underlying lipid-associated inflammation.
Materials and methods

Mouse and human subjects
Six-to 9-week-old mice on a C57BL/6 background were used. CD1d 2/2 mice 41 and Ja 18 2/2 on a C57BL/6 background were kindly provided by Dr Peter
Cresswell (Yale University, New Haven, CT). The generation of conditional GBA knockout mice has been previously described. 42 All mice were bred and maintained in compliance with Yale University's institutional animal care guidelines. Peripheral blood mononuclear cells (PBMCs) from healthy donors were isolated from buffy coats purchased from New York Blood Center or from patients with GD, following informed consents approved by the institutional review board in accordance with the Declaration of Helsinki.
Isolation of human and mice mononuclear cells (MNCs)
CD14
1 monocytes were separated from PBMCs with CD14 magnetic beads (Miltenyi Biotec) using the manufacturer's protocol. MNCs from thymus, spleen, and liver were isolated following a protocol described earlier. 43 
Antibodies and flow cytometry
Data were acquired with the LSRII system (BD Biosciences) and FACSCalibur (BD Biosciences) and analyzed with FlowJo (Tree Star). Doublets were excluded with FSC1-FSC-H linearity. Mouse antibodies (clones) were as follows: anti-CD3e(145-2C11), anti-CD4(RM4-5), anti-CD8(53-6.7), anti-CD19(1D3), anti-B220(RA3-6B2), anti-F4/80(45-4801), anti-IgM(eB121-15F9), anti-IgD (11-26c), anti-CD279/PD1(J43), anti-CD185/CXCR5(SPRCL5), anti-MHC II (M5/114.15.2) (from eBioscience), anti-BCl-6(K112-91), anti-foxp3(MF23), anti-ICOS(15F9), and anti-IL-21(FFA21). The human antibodies anti-CD3e (SK7), anti-CD4(RPA-T4), anti-CD8(SK1), anti-CD45 RA(H100), anti-CD45RO (UCHL1), anti-CD56(MY31), anti-IFN-g(B27), isotype control (MOPC-21), anti-CD19(SJ25C1), anti-CD27 (M-T271), and anti-IL-21(3A3-N2.1) were from BD Pharmingen; anti-TCR Va24(C15) and anti-TCR Vb11 (C21) were from Beckman Coulter; and anti-CD62L(FN50), anti-PLZF(Mags.21F7), anti-CD279/PD1(J105), anti-CD185/CXCR5(MU5UBEE), anti-CD38(HB7), anti-FAS(15A7), and anti-GL7(GL7) were from eBioscience.
Lipids and CD1d tetramer loading
NKT ligand a-galactosyl-ceramide (a-GalCer) was kindly provided by Kirin Breweries (Tokyo, Japan). b-D-GlcCer d 18:1 -C24:1(15Z),C12:0 was from Avanti Polar Lipids. b-D-GlcCer d 18:1 -C22:0 (thin-layer chromatography purity .98%) and lysoglucocerebroside (thin-layer chromatography purity .98%) were from Matreya. Mouse and human empty CD1d tetramer were obtained from the National Institutes of Health (NIH) tetramer facility (Atlanta, GA). A molar loading ratio (lipid to CD1d) of 200:1 was used for tetramerization studies for both mouse and human tetramers as used in other studies. 21, 25 The unloaded multimer control was prepared by mixing CD1d tetramer with the carrier only.
Stimulation of NKT cells in culture
For stimulation with anti-CD3/CD28 beads (Miltenyi Biotec), sorted tetramer-positive cells were stimulated with anti-CD3/CD28 beads in a 96-well U-bottom plate. For some experiments, sorted bGL1-22/LGL1/ a-GalCer tetramer-positive cells were cultured with CD1d-expressing cell line (C1rd cells; kindly provided by Dr Mark Exley, Boston) or mocktransfected control cells at a T-cell: antigen-presenting cell (APC) ratio of 1: 0, as described previously, 22, 44 with or without lipid pulsing.
TCR sequencing
Genomic DNA was isolated from CD1d tetramer flow-sorted bGL1-22/
LGL1-specific T cells or type I NKT cells, and the diversity of TCR was profiled using high-throughput sequencing of rearranged TCR b loci from genomic DNA by Adaptive Biotechnologies (Seattle, WA) as previously described. 45, 46 Injection of lipids C57BL/6, CD1d 2/2 , or Ja18 2/2 mice were injected intraperitoneally with phosphate-buffered saline, a-GalCer (4 mg/mouse), or bGL1-22 or LGL1 (200 mg/mouse) each week for 6 weeks in a volume of 100 mL. The mice were sacrificed 7 days after the last injection.
Microarray analysis
RNA from CD1d tetramer-sorted b-GL122/LGL1-specific T cells or iNKT cells was amplified, labeled, and hybridized on the Affymetrix Human Genome U133 Plus 2.0 microarray chips. The data were analyzed with GeneSpring GX 12.5 (Agilent Technologies) and Partek Genomice Suite (6.6) software, as described previously.
47,48
Statistics
The Student t test was used to compare data between 2 groups. Significance was set at P , .05. Correlation coefficient between 2 variables was calculated with the Pearson correlation test.
Results
Detection of human CD1d-restricted T cells specific for bGL1-22 and LGL-1
In order to detect human CD1d-restricted T cells specific for the GSLs bGL1-22 and its deacylated product, LGL1 ( Figure 1A ), bGL1-22-and LGL1-loaded human CD1d tetramers were used to stain freshly isolated human PBMCs from healthy blood donors. bGL1-22/
LGL1-loaded CD1d tetramer-positive cells consisted predominantly of Va24 Figure 1E ). Both bGL1-22 and LGL1 tetramerpositive T cells were found to express NKT-associated transcription factor PLZF 49 similar to type I NKT cells, but at lower levels ( Figure 1F ). To gain additional insight into the overall spectrum of TCR use by bGL1-22/LGL1 tetramer-positive T cells, we analyzed Vb chain usage of sorted bGL1-22/LGL1-specific T cells by TCR sequencing, which revealed diverse Vb receptor usage among bGL1-22/LGL1-reactive T cells. Together, these data demonstrate that bGL1-22-and LGL1-specific CD1d-restricted human T cells can be detected in human PBMCs, use diverse TCRs, express PLZF, and are phenotypically distinct from a-GalCer-reactive type I NKT cells. In order to further validate the ligand-specificity of tetramer-positive cells, we analyzed the capacity of tetramer-positive cells to respond to specific lipids in culture. Freshly isolated human PBMCs were cultured with a-GalCer, bGL1-22, or LGL1, and interferon-g (IFN-g) production in response to the glycolipids was measured by intracellular staining. We found that bGL1-22/LGL1 was able to stimulate IFN-g production, and this effect was completely blocked by mAb specific to CD1d (Figure 2A-B) . Compared with type I NKT cells, bGL1-22/
LGL1 type II NKT cells secreted lower levels of IFN-g (see MFI in Figure 2B ), suggesting a lower stimulatory capacity of these ligands. Coculture of purified tetramer-positive cells with CD1d-expressing C1R cells confirmed that bGL1-22/LGL1 tetramer-positive T-cell responses to bGL1-22/LGL1 pulsed APCs were CD1d dependent, as the CD1d-negative parental cell line pulsed with either bGL1-22 or LGL1 did not stimulate cytokine secretion ( Figure 2C ). In order to further confirm antigen specificity, bGL1-22/LGL1-specific CD1d-restricted T cells were expanded in culture using respective lipid-loaded human monocyte-derived dendritic cells (DCs). Together, these data demonstrate that bGL1-22/LGL1-loaded CD1d tetramers detect T cells that respond functionally to the specific lipid in a CD1d-dependent manner.
bGL1-22/LGL1-specific type II human NKT cells have different genomic and cytokine profile compared with type I NKT cells
The ability to detect and isolate bGL1-22/LGL1-specific human type II NKT cells allowed us to compare the global gene expression profiles of these cells with type I NKT cells using microarray analysis. Principal component analysis revealed that the gene expression profile signature for bGL1-22 and LGL1-specific T cells both before and after activation with anti-CD3/CD28 beads is distinct from that of type I NKT cells ( Figure 2E and supplemental Table 1 ). Selected genes that are differentially expressed by bGL1-22/LGL1-specific type II NKT (relative to type I NKT) are shown in Figure 2F . Metacore analysis revealed that the top differentially expressed pathways involved DAP12 and Th17 pathways (supplemental Table 2 ). To further confirm the differences observed with respect to cytokines, we compared the cytokine secretion of sorted bGL1-22/LGL1 tetramerpositive cells with type I NKT cells in response to anti-CD3 stimulation. Compared with type I NKT cells, bGL1-22-and LGL1-specific T cells secreted higher levels of interleukin-5 (IL-5), IL-6, IL-10, IL-13, IL-17, granulocyte macrophage colony-stimulating factor, macrophage-derived chemokine, and macrophage inflammatory protein 1b ( Figure 2G ). This response was CD1d dependent, as it was not observed in cocultures with CD1d-deficient APCs ( Figure 2H ), corroborating the antigen specificity of bGL1-22/LGL1-specific type II NKT cells. Together, these data demonstrate that the human type II NKT cells identified here have a distinct genomic and cytokine profile compared with type I NKT cells, alluding to their potential for distinct roles in regulating human immune response.
Detection and phenotypic characterization of murine bGL1-22-and LGL1-specific CD1d-restricted T cells
Murine bGL1-22 and LGL1 tetramer-positive T cells are composed of both CD4 1 (;60% and 62%) and CD8 1 T cells (;35.1% and 29.6%), respectively, in contrast to a-GalCer tetramer-positive type I NKT cells, which are predominantly composed of CD4 1 T cells (;82%) ( Figure 3A ). bGL1-22 tetramer-positive and LGL1 tetramer-positive cells constitute ;0.9% and 0.06% of lymphocytes in spleen and ;4% and 1.5% of lymphocytes in liver, respectively, whereas a-GalCer tetramerpositive type I NKTs represent ;2% of lymphocytes in spleen and ;30% of lymphocytes in liver ( Figure 3B ). Frequency of bGL1-22-specific T cells was higher than LGL1-specific T cells in both splenocytes and liver MNCs ( Figure 3B ). To determine whether murine bGL1-22/LGL1-reactive T cells are a type II NKT population similar to human PBMCs, splenic as well as liver MNCs were simultaneously stained with a-GalCer and bGL1-22/LGL1-loaded CD1d tetramers conjugated to different fluorochromes. Both bGL1-22-and LGL1-specific T cells had a nonoverlapping profile with type I NKT cells ( Figure 3C ). This observation is further validated by the detection of bGL1-22/LGL1 tetramer-positive, but not a-GalCer tetramer-positive, cells in Ja18
mice, which completely lack type I NKT cells. Both bGL1-22-and LGL1-specific T cells were deficient in splenocytes from CD1d
mice, consistent with their CD1d-dependent nature ( Figure 3D ). 
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For personal use only. on July 24, 2017. by guest www.bloodjournal.org From steady-state level ( Figure 4A ). Injection of bGL1-22 or LGL1 increased the frequency of antigen-specific T cells in vivo in the spleen of WT as well as Ja18 2/2 mice ( Figure 4C and supplemental Figures 2 and 3) exhibiting a sustained upregulation of T FH markers CXCR5 hi PD-1 hi ( Figure 4D ), ICOS (supplemental Figure 4) , and IL-21 (supplemental Figure 5) . Contrary to the findings at steady-state level, T FH phenotype was also induced in type I NKT cells following activation by a-GalCer in a Ja18-dependent manner, as expected , underscoring a possible crosstalk between bGL1-22-specific type II NKT cells and type I NKT cells. 5, 7, 50 Together, these data show that murine bGL1-22-and LGL1-specific type II murine NKT cells respond to ligand-specific stimulation in vivo and constitutively express T FH phenotype, in contrast to type I NKT cells, wherein T FH phenotype requires stimulation by a-GalCer. Figure 4G ). In order to evaluate the effect of these lipids on the induction of lipid-specific antibodies, we analyzed the sera from these mice for lipid-specific antibodies by enzyme-linked immunosorbent assay (ELISA). Injection of bGL1-22 and LGL1 led to the induction of corresponding lipid-specific antibodies in WT and Ja18 2/2 mice, but not in CD1d-deficient mice ( Figure 4H ). Injection of a-GalCer also led to some increase in bGL1-22-specific antibodies, albeit less than following the injection of specific ligands. Together, these data indicate that lipid-mediated activation of bGL1-22/LGL1-specific type II NKT cells is associated with the induction of GC B cells and lipid-specific antibodies in vivo in a CD1d-dependent manner. 
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Alteration in GL1/LGL1-specific T cells in a murine model of GD
In order to test if these NKT cells are altered in vivo in the context of a disease state associated with alteration of corresponding lipids, we analyzed mouse models and patients with GD. Mistry et al recently developed a murine model that faithfully recapitulates the clinical phenotype of type I human GD. 42 Therefore, we analyzed T cells from the spleen and lymph nodes of these mice for the presence of bGL1-22-and LGL1-reactive T cells using CD1d tetramers ( Figure 6A ). Compared with WT control mice, GBA 2/2 mice exhibited a .20-fold increase of LGL1-specific T cells ( Figure 6B ). In contrast, compared with the WT control mice, the proportion of , and Ja18 2/2 mice immunized with a-GalCer, bGL1-22, or LGL1. ***P , .0001; **P , .001; *P , .01. ns, nonsignificant; PBS, phosphate-buffered saline. type I NKT cells was strikingly reduced in GBA 2/2 mice ( Figure 6B ).
Therefore, lysosomal GSL accumulation in GBA 2/2 mice was associated with an altered balance of type I vs type II NKT cells.
Concomitant to increase in LGL1-specific T cells in GBA
mice, upregulation of T FH markers in these cells was also observed ( Figure 6C ). 
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To extend the findings from GD mice to patients, we examined the presence of bGL1-22-and LGL1-specific T cells as well as type I NKT cells in PBMCs from GD patients (n 5 20) and compared the findings to healthy donors. Clinical features of the type 1 GD patient cohort are shown in supplemental Table 3 . In contrast to healthy donors, the majority of bGL1-22-and LGL1-specific T cells had a CD45RO 1 memory and T FH phenotype, consistent with ligand-mediated activation in vivo (supplemental Figures 6 and 7) . The proportion of circulating LGL1-specific T cells was significantly increased in GD patients (percent mean 6 SEM: 0.16 6 0.06 vs 1.263 6 0.25, P , .001), whereas the proportion of type I NKT cells was not significantly different ( Figure 7A ). The percentage of LGL1-specific, but not bGL1-22-specific, T cells or type 1 NKT cells correlated with the serum level of chitotriosidase, an established biomarker of clinical disease activity in GD (R 5 0.70; P , .001) ( Figure 7B ). The increase in LGL1-specific T cells was most noticeable in untreated patients (n 5 5), and the levels of these T cells declined after enzyme-replacement therapy ( Figure 7C ). Analysis of cytokine profile in the serum of GD patients revealed an increase in several cytokines (IL-17, IL-6, macrophage inflammatory protein 1b, fms-related tyrosine kinase 3 ligand, IL-8, and soluble IL-2 receptor) ( Figure 7D ), which correlated with the cytokine profile of LGL1-reactive T cells. Together, these data show that as with GD mice, GSL accumulation in GD patients is associated with an altered balance of type I and II NKT cells and, importantly, that disease severity in the GD patients correlates with circulating LGL1-specific NKT cells.
Discussion
Polyclonal type II NKT cells were initially discovered in the context of MHCII 2/2 mice and are currently identified as CD1d-restricted T cells lacking iTCR. 51, 52 In contrast to type I NKT cells, information on functional properties of human type II NKT cells and their dysregulation in the context of human disease is extremely limited. We focused our studies on 2 distinct GSLs, bGL1-22 and LGL1, which are known to be dysregulated in several human metabolic disorders. We show that in contrast to type I NKT cells, 53 bGL1-22-and LGL1-specific type II NKT cells constitutively express T FH phenotype. We also show that these cells have a distinct cytokine profile and provide robust help to B cells. This study therefore identifies a novel pathway mediated by type II NKT-T FH cells for B-cell immunity and inflammation.
b-Glucosylceramide with acyl chains (12:0 and 24:1) was initially identified as a ligand for type I NKT cells. 21 However, recent studies using sulfatide-reactive type II NKT cell hybridoma XV19 and Ja18-deficient IL-4 reporter mice report recognition of b-GlcCer (12:0 and 24:1) by murine type II NKT cells. 24, 26 In contrast to initial findings from Brennan et al, our data pointed to b-glucosylceramide as a ligand for type II as opposed to type I NKT cells. Recent studies have attributed Brennan's initial findings to a contaminating minor lipid species, consistent with endogenous a-linked glucosylceramide. [54] [55] [56] These new studies therefore provide further support to our conclusion that b-GlcCer is primarily a type II ligand. Interestingly, in a small minority of donors/experiments (supplemental Figure 8) , we did observe an increase in human iNKT cells following stimulation with b-GlcCer. This was not specific for individual lipid preparations but rather individual donors and tracked with higher baseline iNKT cells. In light of new studies, underlying reasons may include contaminating lipids or variations in endogenous a-anomeric lipid antigens in humans, which need further study.
In contrast to bGL1-22, LGL1-specific T cells were found to belong exclusively to the polyclonal human type II NKT subset. Phenotypic characterization, TCR sequencing, and transcriptional and cytokine profiling provided additional confirmation that human bGL1-22/ LGL1-specific T cells are distinct from type I NKT cells. Notably, these cells express the NKT-lineage factor PLZF, albeit at lower level than in type I NKT cells. In addition to its well-documented role in type I NKT cells, PLZF was recently implicated in the differentiation of type II NKT cells as well. 26, 57 Crosstalk between type I and II NKT cells is increasingly implicated in the regulation of immunity to pathogens, tumors, and autoimmunity. 5, 7, 50, 58 The mechanism underlying the crosstalk between NKT subsets requires further study and may be more prominent with specific ligands. For example, in our studies, injection of bGL1-22 (but not LGL1) led to reduction in type I NKT cells in vivo. Similar findings have been made in other studies wherein activation of type II NKT cells led to decline in type I NKT cells in vivo. 50 Although human T cells specific for both bGL1-22 and LGL1 can be detected using lipid-loaded CD1d tetramers, the broad pattern of staining that we observed suggests a range of binding affinities. Further studies are needed to better understand the biological significance of this variation. This may be particularly important in the context of TCR usage, as it is possible that there may be some oligoclonality, particularly with higher-affinity type II NKT cells. Oligoclonality has also been observed with sulfatide-reactive type II NKT cells. 16 Multiplex cytokine analysis of sera from GD patients (n 5 29) and healthy subjects (n 5 15). Analytes with significant differences compared with healthy control sera are shown. Data are shown as mean 1 SEM. ***P , .0001; **P , .001; *P , .01. MIP-1b, macrophage inflammatory protein 1b; sIL-2Ra, soluble IL-2 receptor a.
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